Biofrontera Inc. Announces Results From Phase 1 Safety Study Evaluating Photodynamic Therapy With Three Tubes Of Ameluz
Portfolio Pulse from Happy Mohamed
Biofrontera Inc. (NASDAQ:BFRI) has announced positive results from its Phase 1 study evaluating the safety and tolerability of 3 tubes of BF-200 ALA (Ameluz®) in the treatment of actinic keratosis. The results showed no additional safety or tolerability issues compared to the use of one tube. The company plans to present these findings to the FDA in Q4 2021. Biofrontera also announced that patient enrollment in the Phase 3 clinical study evaluating Ameluz®-PDT in combination with the BF-RhodoLED® lamp for the treatment of basal cell carcinoma is complete.
August 28, 2023 | 12:05 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Positive Phase 1 results for Biofrontera's 3-tube Ameluz treatment could potentially lead to FDA approval for broader use, which would be beneficial for the company. Completion of patient enrollment in the Phase 3 study is also a positive development.
The positive results from the Phase 1 study indicate that Biofrontera's 3-tube Ameluz treatment is safe and well-tolerated, which could potentially lead to FDA approval for broader use. This would be a significant development for the company, as it would allow for treatment of a wider affected area and potentially require fewer office visits. The completion of patient enrollment in the Phase 3 study is also a positive development, as it indicates progress in the company's clinical trials.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100